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Immunoglobulin G4-related disease (IgG4-RD) 
is a rare systemic fibro-inflammatory disorder 
comprised of a collection of disorders that 
share specific pathologic, serologic, and clinical 
features. The pathogenesis of IgG4-RD is poorly 
understood; findings consistent with both an 
The year is flying by and it is time for the latest issue 
of LABRAD. This edition of LABRAD is non-
thematic and includes diverse range of up-to-date 
topics in the expanding field of laboratory medicine. 
The LABRAD kicks off with an overview on IgG4 
related diseases and its diagnostic challenges. IgG4-
related disease is a recently recognized syndrome of 
unknown etiology most often occurring in middle-
aged and older men. The Section of Chemical 
Pathology has recently started measuring subclass 
IgG4 in serum which can assist in the diagnosis of 
IgG4-related disease; however confirmed diagnosis 
requires a tissue biopsy of the affected organ. 
Pathological changes in renal transplant biopsies 
either due to immunosuppressive drugs or the 
sequelae of the immunosuppressive state has been 
discussed later on in the newsletter.  One of our 
hematology residents has elaborated on complement-
mediated hemolysis  ‘Paroxysmal Nocturnal 
Hemoglobinuria’ and how it can be diagnosed by 
flow cytometry. 
This issue also includes an article on the utility 
of Beta-D-Glucan and Galactomannan testing in 
diagnosis of invasive fungal infections. Beta-D 
Glucan and Galactomannan are fungal cell wall 
antigens which can be measured in serum or 
bronchoalveolar lavage fluid. These tests have been 
recently introduced in the Section of Microbiology. 
Elevated Beta-D-Glucan and Galactomannan levels 
can help diagnose invasive fungal infections early 
and can also guide in commencement of therapy as it 
An Overview of Immunoglobulin G4-Related 
Disease (IgG4-RD) 
From the Editor’s Desk
Dr Sheharbano Imran
Chemical Pathology
autoimmune disorder and an allergic disorder are 
present.  The common features of IgG4-related 
disease are lymphoplasmacytic tissue infiltration 
usually accompanied by fibrosis, obliterative 
phlebitis, and elevated serum IgG4. However, 
approximately 30% of patients have normal serum 
has both diagnostic as well as prognostic impact.
The pace of change in Laboratory Medicine is 
dizzying; both in numbers of laboratory tests and 
in the complexity of the results, as is the emerging 
need to integrate massive data sets to reach a clinical 
interpretation. The genomic success stories strongly 
suggest that personalized medicine will increase the 
role of clinical laboratories in patient management. 
These changes have profound implications for the 
discipline of Pathology and Laboratory Medicine and 
for how laboratory diagnosticians relate to medicine 
as a whole. LABRAD gives us an opportunity 
to connect to the clinicians, our peers and other 
health care providers. All faculty, technologists and 
residents are encouraged to keep sending articles or 
other contributions (interesting images in cytology, 
test/ procedure updates, and quiz) to us. The 
Department of Pathology and Laboratory Medicine 
members contribute extensively to healthcare, 
education and research arenas. Maintaining our 
visibility as key players in healthcare is crucial to the 
profession, I urge you to please send a small write 
up and photographs of your activities to us so that we 
could share it with all our readers. 
We really hope this issue will provide some cool 
reading on a hot day!
Happy reading 
Dr Lena Jafri
Associate Editor, LABRAD
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Acute kidney injury (AKI) is characterized 
functionally by a rapid decline in the glomerular 
filtration rate (GFR), and biochemically by the 
resultant accumulation of nitrogenous wastes 
such as blood-urea nitrogen and creatinine. It has 
high incidence in hospitalized patients and poor 
prognosis in critically ill patients with a high 
mortality rate. At present, serum creatinine is used 
to measure the GFR and it is the most commonly 
used marker of renal function. Diagnosis of 
AKI still entirely based on an increase in serum 
creatinine or decrease in urine volume. Due to delay 
between changes in serum creatinine and changes 
in GFR inhibits the ability to accurately estimate 
timing of injury and severity of dysfunction 
following injury. Unfortunately, serum creatinine is 
a delayed and unreliable indicator of AKI, for the 
following reasons:
l Serum creatinine level is influenced by multiple 
 non-renal factors, such as age, gender, muscle 
 mass, muscle metabolism, diet, medications, 
 and hydration status.
l In AKI, the serum creatinine level can take 
 several hours or days to reach a new steady   
 state and thus does not reflect the actual 
 decrease in GFR in the acute setting.
Plasma Neutrophil Gelatinase Associated 
Lipocalin (NGAL) a Marker of Acute Kidney 
Injury
Dr Shabnum Khawaja
Chemical Pathology
IgG4 concentrations despite classic histopathological 
and immunohistochemical findings. The hallmark 
histopathological features of IgG4-RD are 
l A dense lymphoplasmacytic (lymphocyte and   
 plasma cells) infiltrate rich in IgG4-positive    
 plasma cells. 
l Fibrosis, arranged at least focally, in a storiform   
 pattern. ‘Storiform’ is commonly referred to as  
 meaning ‘having a cartwheel pattern’, but its 
 literal meaning is the appearance of ‘a woven mat’
l The venous channels are obliterated by a dense 
 lymphoplasmacytic infiltrate, within both the 
 venous walls and the lumen.
Other histopathological features associated with 
IgG4-RD are phlebitis without obliteration of the 
lumen and/or tissue with increased numbers of 
eosinophil. 
IgG4-RD can involve one or multiple sites in 
the body (salivary gland, orbits, pancreas, Para 
nasal sinus, lacrimal gland, thyroid, pleura, lymph 
nodes etc.). With multiorgan involvement, the 
sites involved can be affected at the same time 
(synchronously) or at different unrelated periods 
(metachronously). However, Type 1 autoimmune 
pancreatitis is the most frequent manifestation of this 
disease. Following medical conditions that have long 
been viewed as conditions confined to single organs 
are part of the spectrum of IgG4-related disease: 
autoimmune pancreatitis, Mikulicz disease, Kuttner’s 
tumor, Riedel thyroiditis, eosinophilic angiocentric 
fibrosis, multifocal fibrosclerosis, inflammatory 
psuedotumor, fibrosing mediastinitis, sclerosing 
mesenteritis, retroperitoneal fibrosis, periaortitis/ 
periarteritis, inflammatory aortic aneurysm, 
cutaneous pseudolymphoma, idiopathic hypertrophic 
pachymeningitis, idiopathic tubulointerstitial nephritis, 
, idiopathic hypocomplementemic tubulointerstitial 
nephritis with extensive tubulointerstitial deposits and 
idiopathic cervical fibrosis.
Early detection is important to avoid organ damage 
and potentially serious complications. Diagnosing 
IgG4- RD is challenging and the awareness of this 
disease is low. The Clinical Laboratory of Aga Khan 
University Hospital has initiated the testing serum 
IgG4 which can assist in the diagnoses of IgG-4 
related diseases.
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Celiac Disease (CD) or gluten-sensitive enteropathy 
is an autoimmune disease caused by ingestion of 
gluten-containing cereals, in genetically predisposed 
individuals. It is characterized by inflammation 
and atrophy of the small intestinal villi, leading to 
reduced nutrients absorption. Clinical symptoms of 
CD are fatigue, abdominal pain, diarrhea, effects 
of malabsorption such as weight loss and growth 
retardation in children, vomiting, constipation, 
and bone pains. CD patients may also manifest 
with symptoms of nutritional deficiencies such 
as osteoporosis, anemia, neuropathies, carditis, 
pregnancy problems, or lymphoma. The only effective 
treatment for CD is adherence to a gluten-free diet. 
The prevalence of symptomatic CD is around 
one percent. The frequency of CD is substantially 
increased in patients who have a first-degree family 
member affected with CD. However, most cases 
remain undiagnosed, only patients with classical 
variant are investigated and represent only the 
tip of the celiac iceberg. Recently, it has become 
increasingly evident that CD exists not only in 
its classical form, but also more frequently in 
asymptomatic or silent forms. These patients do 
not have symptoms, but they exhibit CD specific 
antibodies and villous atrophy. So a disease which 
was once believed to be a rare enteropathy of 
childhood is now considered to be a much more 
Celiac Disease: Biomarkers for Diagnosis and 
Monitoring
Dr Hafsa Majid
Chemical Pathology
l Because of renal reserve, the serum creatinine 
 level may not rise until more than 50% of the 
 kidney function has been lost.
l An increase in the serum creatinine level 
 represents a delayed indication of a functional 
 change in GFR that lags behind structural 
 changes that occur in the kidney during the 
 early stage of AKI.
l Serum creatinine measurement does not 
 allow differentiation between hermodynamically  
 mediated changes in renal function, such as   
 pre-renal azotemia from intrinsic renal failure or  
 obstructive uropathy.
NGAL for the prediction of AKI
Neutrophil gelatinase-associated lipocalin (NGAL) 
is a single disulphide-bridged polypeptide chain of 
178 amino-acid residues with a molecular mass of 
25kDa. It is a small protein expressed in neutrophils 
and certain epithelia, including the renal tubules. 
In healthy person it filtered out of plasma by the 
glomeruli when it passes through the kidneys then 
reabsorbed back into plasma in the tubules. In kidney 
inflammation its expression is greatly increased as a 
human immune response to inflammation and injury 
to epithelia and accumulation of in blood plasma, 
with increased concentrations in plasma and urine, 
could indicate AKI.
It is to be one of the earliest and most robustly 
induced proteins in the kidney after ischemic or 
nephrotoxic AKI. Its levels rise within two hours 
of the insult, making it as an early and sensitive 
biomarker of AKI. Plasma NGAL is a biomarker 
for the early prediction of AKI following defined 
clinical injuries such as cardiopulmonary bypass, 
contrast administration and kidney transplantation. 
Plasma NGAL can also be used for the early 
prediction of AKI, even in heterogeneous clinical 
situations where the timing of kidney injury is 
unknown, such as in the critical care or emergency 
settings. NGAL levels can also discriminate 
between true AKI and prerenal azotemia in 
unselected patients presenting for emergency 
care. Reduction in NGAL levels are becoming 
increasingly used as an efficacy marker in trials 
for the prevention and/or  treatment of AKI. Early 
plasma NGAL concentrations are predictive of 
dialysis requirement, mortality and length of 
hospital stay in a variety of clinical AKI situations. 
NGAL is emerging as an excellent standalone 
troponin-like biomarker for the prediction of 
AKI and its clinical outcomes. It not only aids in 
diagnosis but levels also correlate with the severity 
of the AKI and with patients outcomes.
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common multi-organ disease. The exact prevalence 
of CD in Pakistan is not known, but it is felt to be a 
common disorder present in all four provinces. 
Disease Pathogenesis
The cause of the pathological process leading to CD 
is prolamins, which are protein components of gluten 
found in many types of cereal. Gliadin is the most 
common occurring prolamin. Prolamins are only 
partly digested in the small intestine. The resulting 
peptides are taken up into the intestinal wall and 
deamidated by the enzyme tissue transglutaminase 
(TTG). The immune system of affected individuals 
is genetically predisposed to develop immune 
reactions against both the deamidated peptides and 
transglutaminase. These reactions cause chronic 
inflammation and atrophy of the small intestinal villi.
Diagnosis of CD
In recent years, advances in laboratory diagnostic 
tests for CD have transformed the way the disease 
is diagnosed and monitored, reducing the number 
of small bowel biopsies performed significantly. 
The target antigens are divided into two groups, first 
group includes autoantibodies [Anti endomysial 
(EMA) and anti-TTG] antibody tests, and second 
group comprise antibodies targeting the offending 
agent, gliadin. Key laboratory investigations 
comprise the determination of autoantibodies against 
TTG or endomysium (EmA), antibodies against 
deamidated gliadin peptides and the CD-associated 
human leukocyte antigens (HLA) DQ2 and DQ8. 
Newly published guidelines confirm the pivotal role 
of serological testing in CD diagnostics.
The European Society of Paediatric 
Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) and American College of 
Gastroenterology guidelines on ‘Diagnosis and 
Management of Celiac Disease’ recommend the 
following:
l In patients with CD, Immunoglobulin-A   
 (IgA) TTG antibody is the preferred single test in  
 individuals over the age of two years. 
l In high-probability patients both IgA and IgG-
 based testing, such as IgG-deamidated gliadin 
 peptides (DGPs) and IgA-TTG should be done 
 and intestinal biopsy should be pursued even if 
 serologic tests are negative.
l If the anti-TTG antibody titer is very high 
 (>10 times upper normal limit), and if this 
 result is reinforced by other positive serology 
 and compatible HLA, it is not necessary to 
 perform a biopsy. 
l In subjects suspected of low IgA or selective IgA  
 deficiency, total IgA and IgG-based testing (IgG- 
 DGPs and IgG-TTG) should be performed. 
l In patients on a gluten-containing diet all   
 diagnostic serologic testing should be done. 
l Combining several tests for CD rather than 
 IgA-TTG alone may increase the sensitivity for 
 CD, especially in high risk group. 
l Screening children younger than 2 years of age, 
 the IgA TTG test should be combined with DGP 
 (IgA and IgG). 
Diagnostic tests should be carried out in individuals 
on a gluten-containing diet. A gluten challenge is 
only performed under exceptional circumstances.
Antibodies against Tissue Transglutaminase
Autoantibodies against TTG are the most important 
serological markers for CD. They are alternatively 
known as EmA, depending on the testing 
method used: EmA are determined using indirect 
immunofluorescence, while anti-TTG is detected 
using immunoassay test systems such as ELISA.
EmA and anti-TTG antibodies of immunoglobulin 
class IgA possess a very high sensitivity and 
specificity for CD. They virtually never occur in 
healthy individuals or patients with other intestinal 
diseases, whereas in untreated CD their prevalence is 
near 100 percent. Enzyme immunoassays for detection 
of anti-TTG antibodies are preferred due to their 
simplicity, cost-effectiveness, and automatability, 
combined with their high sensitivity and specificity. 
A multitude of clinical studies have confirmed the 
efficacy of ELISA method, yielding a sensitivity of 90 
percent to 100 percent and a specificity of 95 percent 
to 100 percent for active CD.
Antibodies against deamidated gliadin peptides
Antibodies against gliadin also occur in patients 
with CD, and their determination strengthens a 
diagnosis. Recent scientific knowledge has revealed 
that only a tenth of the epitopes of the gliadin 
molecule are diagnostically relevant, and these must 
be present in deamidated form. These immunoassays 
assays provide significantly higher sensitivity and 
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Pathophysiology of Paroxysmal Nocturnal 
Haemoglobinuria and Diagnosis  by 
Flowcytommetry
Dr Nadia Nasir 
Hematology
Paroxysmal Nocturnal Hemoglobinuria (PNH) 
is a rare, acquired stem cell disorder caused by 
a somatic mutation in the X-linked PIG-A gene. 
The PIG-A protein is involved in the initial stage 
of synthesis of the glycosylphosphatidyl-inositol 
Figure 1: Pathogenesis of PNH adapted from Haematologica April 2010 
95: 523-526
(GPI) anchors. There is a partial or absolute 
defect in the biosynthesis and expression of 
glycophosphatidylinositol V (GPI) linked structures 
including CD55 and CD59 on red cells. Absence 
of these anchors on red cells is largely responsible 
for intravascular hemolysis associated with clinical 
PNH.
PNH has three distinctive clinical features that 
vary greatly from patient to patient and during the 
course of the disease. First, there is complement 
mediated and predominantly intravascular hemolysis. 
These result in clinical features such as, erectile 
dysfunction, chronic renal failure, pulmonary 
hypertension, anemia, and,hemoglobinuria.
Second, there is a characteristic thrombotic tendency 
that occurs in extremities along with  hepatic portal 
(Budd-Chiari Syndrome), splenic, or mesenteric 
veins.
Third, there is underlying bone marrow failure, 
which occurs to some degree in all patients, and in 
specificity than conventional anti-gliadin assays. 
Multiple studies have shown that the new test yielded 
sensitivity (at 95 percent specificity) of 83 percent/94 
percent (IgA/IgG). 
Anti-DGP antibodies are a relatively new biomarker 
for CD diagnosis and management, recently this 
marker is introduced at clinical laboratories of Aga 
Khan University. Use of the anti-DGP antibodies 
in combination with the anti-TTG are shown to 
significantly increase the serological detection rate 
for CD. This biomarker is particularly valuable for 
identifying CD patients with an IgA deficiency, 
which is frequently associated with CD and in 
situations where biopsy cannot be performed due 
to any reason. Determination of antibodies against 
deamidated gliadin is also suitable for assessing 
disease activity and for monitoring a gluten-free diet 
or a gluten-load test. 
In conclusion the confirmation of a diagnosis of CD 
should be based on a combination of findings from 
the medical history, physical examination, serology, 
and upper endoscopy with histological analysis of 
multiple biopsies of the duodenum. While patients 
with CD should be monitored regularly for residual 
or new symptoms, adherences to gluten free diet 
and assessment for complications. Monitoring of 
adherence to gluten free diet should be based on a 
combination of serology (IgA-TTG or IgA/IgG-DGP 
antibodies). In children, special attention to assure 
normal growth and development is recommended. 
References:
A. R. Tapia et al. ‘ACG Clinical Guidelines: Diagnosis and 
Management of Celiac Disease’. The American Journal of 
Gastroenterology. Vol 108; May 2013.
S. Husby et al. ‘European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition Guidelines for the Diagnosis of 
Coeliac Disease’. JPGN. Volume 54; Jan 2012.
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Pathological Changes in Renal Transplant 
Biopsies not Related to Allo-Immune 
Mechanisms 
Dr Mohammad Usman and Dr Saroona Haroon
Histopathology 
its most extreme form, presents as immune-mediated 
severe aplastic anemia.
Diagnosis by Flow Cytommerty
1. RBC Antigen Assays 
These were the first used to detect PNH because 
DAF (CD55) and MIRL (CD59) were recognized 
early on as the proteins whose deficiency was central 
to the pathophysiology of PNH.  However testing 
of RBCs alone in a routine assay is not adequate 
for evaluation of these patients, because during 
acute hemolytic episodes, inadequate red blood 
cells are available for testing, hence such assays can 
undersestimate the size of a PNH clone. 
2. Leukocyte Analysis
Assessment of PNH populations in leukocytes is 
widely recognized as the best method for  assessing 
the true size of a PNH clone especially monocytes 
and granulocytes. Lymphocytes are not a suitable 
target because of their long life span and variable 
expression of many GPI-linked proteins. Both 
monocytes and neutrophils are analysed together to 
increase sensitivity of the test. Monocytic markers 
include CD14 and CD33 whearas  granulocytic 
markers include CD66.
3. Analysis by FLAER
One of best reagents available to study GPI-linked 
antigens on leukocytes is the reagent fluorescent 
aerolysin or FLAER. This is a fluorochrome-
conjugated inactive variant of the bacterially derived 
protein aerolysin, which binds specifically to the 
Image adapted from Guidelines for the Diagnosis and Monitor-
ing PNH and Related disorders by flowcytometry; Cytometry 
Part B (Clinical Cytometry) 78B:211–230 (2010)
GPI anchor and is absent from GPI anchor–deficient 
granulocytes and monocytes.
A: Initial gate set on a CD45/SSC shows both 
granulocytes and monocytes
B: Display of CD33 vs. CD15. Granulocytes 
(CD15 high, CD33) low are clearly separated from 
monocytes (CD15 low CD33 high) and are easily 
distinguished. 
C: Display of FLAER and CD24 on the CD15 
population showing a clear double negative PNH 
granulocyte population. 
D: Display of FLAER and CD14 on the CD33 
positive population showing a clear double negative 
PNH monocyte population. 
In renal transplant recipients, a variety of factors 
lead to renal damage apart from the allo-immune 
reactions. These morphologic features observed in 
these conditions can be either directly related to 
immunosuppressive drugs or the sequelae of the 
immunosuppressive state. Protocol for obtaining 
and evaluation of renal biopsy in these conditions is 
similar to that of a non-transplant biopsy.  
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Calcineurin Inhibitor (CNI) Drug Toxicity
Calcineurin inhibitors (CNIs) including 
cyclosporine (CsA) and tacrolimus are used for 
maintenance immunosuppression after solid organ 
transplantation. These drugs have the potential to 
cause both acute and chronic nephrotoxicity. Acute 
CNI toxicity is one of the important causes of acute 
graft dysfunction. Acute tubular injury (ATI) is the 
most common lesion, accompanied by isometric 
vacuolization of tubular epithelial cell cytoplasm. 
Both drugs also cause thrombotic microangiopathy 
(TMA) and microvascular toxicity which manifests 
as endothelial cell swelling, mucinous intimal 
thickening, nodular hyalinosis, and focal medial 
necrosis. Chronic CNI toxicity results in nodular 
arteriolar hyalinosis (Figure-1), characterized by 
hyaline, eosinophilic deposit consisting of fibrin, 
IgM, C3, and C1q. The ischemic injury caused by 
vasculopathy leads to interstitial fibrosis. 
Infections
Urinary tract infections are common in the 
early post-transplant period as the recipients are 
predisposed to bacterial, fungal, protozoal, and viral 
infections due to immunosuppression. 
The infective agents may affect the allograft or the 
native organs of the recipient. Bacterial infections 
result in a mixed inflammatory cell infiltrate in the 
interstitium associated with tubular microabscesses.
Cytomegalovirus (CMV) and polyoma (BK) viruses 
are important causative agents (Figure 2).
Post-Transplant Lymphoproliferative Disorder 
(PTLD)
It is a rare disorder which is an important 
differential diagnosis with acute cellular rejection 
and an early diagnosis of this complication is 
necessary for its successful management. PTLD is 
characterized by a monomorphic or polymorphic 
lymphocytic infiltrate containing plasma cells, 
many of which are atypical. There is typically a 
diffuse interstitial infiltrate without associated 
tubulitis or arteritis. Immunophenotyping of 
lymphocytes helps in the definite diagnosis of its 
concurrence with rejection. 
Acute Tubular Necrosis (ATN)
Acute tubular injury (ATI) or ATN is the main 
cause of primary nonfunction of the allograft. ATI 
results from a multitude of causes and including 
in situ injury in the donor; ischemia during organ 
harvesting, storage, or transportation of the organ; 
and ischemic injury incurred perioperatively in the 
recipient. The morphological picture is similar to 
that seen in the native kidneys. The histological 
features of ATN do not correlate well with the 
allograft function. 
Acute Tubulointerstitial Nephritis (ATIN)
Non-immune related ATIN may result from 
a number of insults such as infection, drug 
hypersensitivity, viral infection, etc. A 
predominance of neutrophils in the mixed 
inflammatory cell infiltrate in the interstitium, 
especially if associated with tubular microabscesses 
or leucocyte casts favor the possibility of infection. 
A predominance of eosinophils raises the possibility 
of drug hypersensitivity. Viral infections are 
accompanied by appropriate viral cytopathic effects 
in addition to the infiltrate. 
Recurrent and De Novo Renal Diseases
Almost all diseases that occur in the native kidneys 
can occur de novo or recur in transplant kidneys. 
Figure 2: Polyoma (BK) virus infection. Epithelial cells exhibiting 
intranuclear viral inclusions.
Figure 1: CNI toxicity manifesting as vasculopathic changes including 
nodular hyalinosis of arteriolar wall and intimal thickening.
10
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Myelodysplastic Syndromes
The Myelodysplastic syndromes (MDS) are a 
group of clonal disorders of the bone marrow. Their 
common feature is bone marrow failure as a result 
of ineffective haematopoiesis rather than reduced 
haematopoietic activity. MDS is predominantly a 
disease of the elderly, although it may affect all ages. 
It can arise de novo or follow previous chemotherapy 
or radiotherapy for another malignancy.
Classification
French-American-British (FAB) classification
In 1974 and 1975, a group of pathologists from 
France, the US, and Britain produced the first widely 
used classification of these diseases. This - French-
American British classification was published in 
1976, and revised in 1982.
Dr Aeysha Majeed 
Hematology
Table 1: (adapted from text book Postgraduate Haematology by Hoffbrand 6th edition)
Name Description
Refractory anemia (RA  Characterized by less than 5% primitive blood cells (myeloblasts) in the bone marrow and
pathological abnormalities primarily seen in red cell precursors
 Refractory anemia with ring
 sideroblasts (RARS
 Also characterized by less than 5% myeloblasts in the bone marrow, but distinguished by the
 presence of 15% or greater red cell precursors in the marrow being abnormal iron-stuffed cells
”called ”ringed sideroblasts
Refractory anemia with excess 
blasts (RAEB) 
Characterized by 5-20% myeloblasts in the marrow
 Refractory anemia with excess
 blasts in transformation
((RAEB-T
 Characterized by 21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid
(leukemia
 Chronic myelomonocytic
 leukemia (CMML), not to
 be confused with chronic
myelogenous leukemia or CML
 Characterized by less than 20% myeloblasts in the bone marrow and greater than 1*109/L
.monocytes (a type of white blood cell) circulating in the peripheral blood
World Health Organization
Most recently, the WHO has evolved a new 
classification scheme (2008) which is based more 
on genetic findings. However, morphology of 
the cells in the peripheral blood, bone marrow 
aspirate, and bone marrow biopsy is still the 
screening test used in order to decide which 
classification is best and which cytogenetic 
aberrations may be related.
Glomerular diseases account for approximately 
10-20 percent of cases of ESRD undergoing 
transplantation, and overall approximately 20 
percent of these patients experience recurrence. 
The same disease can also occur as de novo 
disease in the transplanted kidneys. Disease 
characteristics of the recurrent disease are similar 
to those of the original disease, but are usually 
mild in nature. The two most common diseases 
are membranous glomerulonephritis and focal 
segmental glomerulosclerosis. A non-glomerular 
disease that frequently recurs in transplanted 
kidneys is the primary hyperoxaluria, if kidney 
transplantation is carried out without concomitant 
liver transplantation.
Conclusion
Knowledge of the pathologic features either 
related to allo-immune rejection or other 
conditions in post-transplant patients is 
necessary to identify, prevent and minimize 
the damage by administering proper treatment 
and management. 
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Old System New System
Refractory anemia (RA) Refractory cytopenia with unillineage dysplasia (Refractory anemia, Refractory neutropenia 
and Refractory thrombocytopenia) 
Refractory anemia with ringed sid-
eroblasts (RARS)
Refractory anemia with ring sideroblasts (RARS)
Refractory anemia with ring sideroblasts – thrombocytosis (RARS-t) (provisional entity) 
which is in essence a myelodysplastic/myeloproliferative disorder and usually has a JAK2 
mutation (janus kinase) – New WHO classicication 2008
Refractory cytopenia with multilineage dysplasia’ (RCMD)’ includes the subset Refractory 
cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). RCMD includes pa-
tients with pathological changes not restricted to red cells (i.e., prominent white cell precursor 
and platelet precursor (megakaryocyte) dysplasia. 
Refractory anemia with excess blasts 
(RAEB)
Refractory anemias with excess blasts I and II. RAEB was divided into RAEB-I (5-9% 
blasts) and RAEB-II (10-19%) blasts, which has a poorer prognosis than RAEB-I. Auer rods 
may be seen in RAEB-II which may be difficult to distinguish from acute myeloid leukemia.
Refractory anemia with excess blasts 
in transformation (RAEB-T)
This category was eliminated, such patients are now considered to have acute leukemia
5q -  syndrome, typically seen in older women with normal or high platelet counts and 
isolated deletions of the long arm of chromosome 5 in bone marrow cells, was added to the 
classification.
Chronic myelomonocytic leukemia 
(CMML)
CMML was removed from the myelodysplastic syndromes and put in a new category of 
myelodysplastic-myeloproliferative overlap syndromes.
Myelodysplasia unclassifiable (seen in those cases or megakaryocyte dysplasia with fibrosis 
and others)
Refractory cytopenia of childhood (dysplasia in childhood) – New in WHO classification 
2008
Table 2: (adapted & modified from text book Postgraduate Haematology by Hoffbrand 6th edition).
Diagnosis
Morphology
The diagnosis of MDS depends on careful 
morphological examination of the blood film and 
bone marrow aspirate and  trephine specimens. 
Common abnormalitiesinclude:
l  Peripheral blood. Red cells – anisopoikilocytosis, 
 macrocytosis. Neutrophils – hypogranulation 
 (decrease granules), pseudo- Pelger forms(bi-lobed  
 neutrophils). Platelets – giant forms (large sized).
l  Bone marrow. Erythroid cells – multinuclearity, 
 nuclear budding, ring sideroblasts. 
 Myeloid cells show hypogranularity, increased 
 blast cells. Megakaryocytes – giant forms or 
 micromegakaryocytes.
Where there are changes in all three lines the 
term ‘trilineage dysplasia’ is used. The bone 
marrow trephine biopsy usually confirms marrow 
hypercellularity, although fibrosis and even 
hypocellularity may occur.
Genetics
 
Around 50 percent of cases of MDS show 
cytogenetic abnormalities. Common changes include 
monosomy 7 or 7q−, trisomy 8and  monosomy 5 or 
5q−. The incidence of chromosome abnormalities 
increases with the severity of the disease and risk of 
leukaemic transformation. 
Management
The goals of therapy are to control symptoms, improve 
quality of life, improve overall survival, and decrease 
progression to acute myelogenous leukemia (AML). The 
International Prognostic Scoring System (IPSS) – based 
on the number of blood cytopenias, percentage of bone 
marrow blasts and karyotype – is simple prognostic tool 
which can be used to direct treatment.Supportive care 
with blood product support and hematopoeitic growth 
factors (e.g. erythropoietin) is the mainstay of therapy.
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Fluorescent Optical Method for Platelet 
Estimation: An Advanced Clinical Parameter 
in Laboratory Hematology
Noor Rahman Khan and Muhammad Shariq Shaikh
Hematology
Platelets, also called ”thrombocytes”, are a 
component of blood whose function (along with 
the coagulation factors) is to stop bleeding by 
clumping and clogging blood vessel injuries.  
Platelets are cytoplasmic fragments of 
megakaryocytes of the bone marrow and hence 
lack nucleus. Approximately 70 to 80 percent of 
platelets circulate in the blood, 20 to 30 percent 
are stored in the spleen. A normal platelet count 
ranges from 150,000 to 450,000 platelets per 
microliter of blood. 
Complete blood count (CBC) is a basic test 
ordered routinely by physicians as a part of initial 
diagnostic work-up on their patients. Platelet 
count estimation is an important integral part of 
a CBC report and its reliability is highly desired 
in the diagnostic and treatment process of several 
clinical conditions. For instance, it is very 
important to know the accurate platelet count 
of a patient with thrombocytopenia to decide 
appropriate treatment strategy particularly when 
platelet transfusion is also being considered.
Various methods for platelet estimation can be 
utilized like microscopy using a haemocytometer, 
immunophenotyping utilizing monoclonal 
antibodies and a flow cytometer, impedance 
method and the fluorescent optical method. 
The majority of modern automated hematology 
analyzers in use incorporate the impedance 
method for platelet estimation. 
In impedance measurement (resistance measuring 
principle), cells are passed one after the other 
through a capillary opening. The passing cell 
produces an electrical resistance and thus an 
electronic signal which is proportionate to its 
volume. Hence, the cells are identified based on 
their size. In a normal specimen, erythrocytes 
which also are non-nucleated cells can be 
clearly distinguished from platelets based on 
difference in their size. However in pathological 
conditions, where platelets are larger than 30 fL 
(e.g. large and giant platelets in Bernard-Soulier 
Syndrome) or when erythrocytes are smaller than 
25 fL (e.g. red cell fragmentation syndromes 
or microcytosis) a clear separation may not be 
achieved. In such cases, platelet count must be 
verified by an alternate method.
Fluorescent optical method of platelet estimation 
is an advanced technique in which the platelet 
RNA is first stained with a patented fluorescence 
dye specifically developed for diode lasers. 
Subsequently, the platelets are recorded flow-
cytometrically by means of semi-conductor 
laser technology. As erythrocytes and platelets 
differ in their RNA content, this nucleic acid 
staining enables the analyzer system to properly 
differentiate platelets from other cells.
Several models of Sysmex X-class hematology 
analyzers incorporate this sophisticated 
optical method of platelet estimation. At 
AKUH clinical laboratories, the state-of-the-
art Sysmex XE-5000 automated hematology 
analyzer (Sysmex Corporation, KOBE, JAPAN) 
can perform platelet counts by both impedance 
and optical methods. In case of interference in 
the platelet impedance count, the instrument 
automatically alerts the user to switch to 
optical method. An automatic algorithm using 
pre-defined criteria can also be activated for 
this purpose. Thus fulfilling the requirements 
of good laboratory practice, an accurate and 
precise platelet count result is reported on 
every patient specimen. 
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Fungi are increasingly reported as major pathogens 
in critically ill and immunocompromised patients. 
Invasive fungal diseases are important causes of 
morbidity and mortality today. Several factors are 
considered to contribute in the increasing trend of 
invasive fungal infections, including hematological 
malignancies, stem cell transplantation, use of 
chemotherapeutic drugs and immunosuppressive 
agents, broad-spectrum antibiotics, prosthetic 
devices and grafts, and more aggressive surgery. 
Patients with burns, neutropenia and HIV infection 
are also predisposed to fungal infections. Yeasts 
most frequently seen in clinical practice are Candida 
spp and Cryptococcus spp. The most frequent 
filamentous fungi (molds) isolated are Aspergillus 
spp., but Fusarium spp., Scedosporium spp. and 
Mucoraceous molds are increasingly seen. 
The symptoms of invasive fungal infections (IFI) 
are nonspecific which can impede timely diagnosis. 
Definitive diagnosis of invasive fungal infections 
requires cultures of tissue, blood, or other fluids. 
Routine diagnostic tests are time consuming, so 
empirical treatment can be commenced, based on 
clinical suspicion, which can also make a specific 
fungal diagnosis difficult. Fungal infections of the 
airway may be evident on chest radiography or 
computed tomography. Bronchoscopy is also used to 
better visualize the infected area and to obtain tissue 
samples.
Aspergillosis is common in patients with 
hematological malignancies. Invasive 
aspergillosis manifests primarily as pneumonia 
or sinus infections, or asymptomatic lesions in 
the lung parenchyma. It is rapidly progressive 
and can disseminate hematogenously. Definitive 
diagnosis of Invasive Aspergillosis (IA) can be 
made on histopathology and culture on biopsy 
tissue from suspected site. Obtaining such 
specimens can be a hurdle as it requires invasive 
procedure, which is not always possible and can 
delay diagnosis in this regard.
Current guidelines regarding diagnosis of IFI 
recommends use of fungal cell wall antigens like 
Beta-D Glucan and galactomannan in serum or 
Bronchoalveolar lavage (BAL) fluid. Beta-D glucan 
is a found in most fungi, both yeasts and molds, 
while galactomannan is specific to Aspergillus. High 
levels can be detected in serum or BAL fluid, which 
can help diagnose IFI early and can also guide in 
commencement of therapy as it has both diagnostic 
as well as prognostic impact. Use of these antigens in 
diagnosis and monitoring of IFIs has led to decrease 
in unnecessary use of antifungals. 
Galactomannan levels, however, can be falsely 
normal, especially if the patient is already on 
antifungal treatment. Falsely normal levels 
are also witnessed in chronic granulomatous 
diseases and Job’s syndrome. Falsely positive 
results are seen in patients with altered intestinal 
barrier (galactomannan is also found in certain 
foods e.g. cereals), in patients on treatment with 
piperacillin-tazobactam or amoxicillin-clavulanate 
and in patients infected with Penicillium, 
Histoplasma, Alternaria, Paecilomyces or 
Geotrichum. Beta-D Glucan levels usually do 
not rise in infections due to mucoraceous molds 
(Rhizopus, Mucor) and Cryptococcus neoformans. 
Falsely high results are seen when patient is 
on beta lactam antibiotics or hemodialysis or if 
specimen is contaminated with talc. 
Regarding galactomannan, a single positive index 
of >0.7 or two consecutive samples of >0.5 in 
serum is considered to be positive and < 0.5 is 
negative. Serum value of >1.0 is considered a sign 
of therapeutic failure. In BAL sample, a single 
positive index of >1.0 is positive. In CSF sample a 
single positive index of >0.5 is positive. For Beta-D 
Glucan, data for neonates and infants less than 
six months are lacking. It is considered positive if 
levels are >80 pg/ml, Indeterminate if 60-80 pg/ml 
(repeat test recommended) and negative if levels 
are <60 pg/ml.
Introduction of Beta-D-Glucan and 
Galactomannan Testing for Diagnosis of 
Invasive Fungal Infections 
Dr Tazeen Fatima
Clinical Microbiology 
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These tests have been introduced in Clinical 
Microbiology Laboratory at Aga Khan University 
Hospital. These investigations can be done in 
patients with high clinical suspicion of IFI like 
Hematopoietic stem cell transplantation (HSCT) 
is the therapeutic modality of transplanting blood 
containing hematopoietic stem cells for treating 
refractory blood diseases like leukemia and aplastic 
anemia, some solid tumors and also refractory 
autoimmune diseases.
Hematopoietic stem cells are cells that in due 
course become RBCs, WBCs and platelets. These 
have regenerative capacity and are located in bone 
marrow but can be mobilized to peripheral blood 
due to G-CSF, severe infections and treatment with 
antineoplastic drugs. Cord blood also contains 
these cells. Accordingly HSCT can be classified 
as per type of blood that contains these stem cells 
into: Bone marrow transplant (BMT), Peripheral 
Basic Concepts in Hematopoietic Stem Cell 
Transplantation
Dr Muhammad Hasan 
Haematology
aspergillosis, candidemia, etc. The results must 
always be correlated to the clinical history, 
radiological findings and culture results before 
making the final diagnosis.
blood stem cell transplant (PBSCT) and Cord blood 
transplant (CBT).
It can also be classified a/c to source of stem cells 
into:
 1. Autologous: When transplanted blood is of  
  patient him/herself.
 2. Allogeneic: When the blood is obtained 
  from another person.
  a. Syngeneic: if donor is identical twin.
  b. Allogeneic related: If donor is blood 
   relative other than an identical twin
  c. Allogeneic unrelated: When donor is an  
   unrelated person.
Common Indications:
Autologous
Multiple myeloma
Non-Hodgkin lymphoma
Hodgkin disease
Acute myeloid leukemia
Neuroblastoma
Germ cell tumors
Autoimmune disorders - SLE, systemic sclerosis
Amyloidosis
Allogeneic
AML,  ALL , MDS
CML and other MPDs
Chronic lymphocytic leukemia
Multiple myeloma
Non-Hodgkin lymphoma and Hodgkin disease
Thalassemia major and  Sickle cell anemia
Inherited bone marrow failure syndromes
Aplastic anemia, PNH and pure red cell aplasia
Severe combined immunodeficiency (SCID)
Inborn errors of metabolism - Eg,     
mucopolysaccharidosis and Gaucher disease
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HSCT Procedure
Selection of donor (for allogeneic HSCT 
Stem cells are normally obtained from an HLA 
matched donor (Usually sibling). When no donor is 
available among blood relatives, a search is made 
for an unrelated matched donor. Allogeneic HSCT 
is also possible even if there is not a perfect HLA 
match between donor and patient (mismatch HSCT), 
but the chance of severe GVHD and graft failure is 
high.  Once the donor is identified, he is screened for 
general health and well being.
Pretransplant Conditioning 
The patient is given chemotherapy and 
radiotherapy to kill all cancer cells and to 
eliminate or weaken normal blood cells, to 
create favorable environment for transplanted 
stem cells to get grafted. This makes the patient 
immunocompromised so there is need of isolation 
in bio clean room and provision of antifungal, 
antiviral and antibacterial drugs. Conditioning 
starts approx 7-10 days before transplantation of 
stem cells.   
Harvesting Hematopoietic Stem Cells 
From bone marrow: It is done under general 
anesthesia, through a bone marrow aspirate needle by 
repeatedly inserting it into the iliac bone to acquire 
the bone marrow in amount 15ml/kg of patient’s 
body weight. A dose of 1 X 108 and 2 X 108marrow 
mononuclear cells per kilogram are required to 
establish engraftment in autologous and allogeneic 
marrow transplants, respectively.
From peripheral blood:  Stem cells are collected once 
they peak in peripheral blood after the administration 
of G-CSF. This is done using blood cell separator 
(Aphresis) which efficiently separates a fraction 
of stem cells through centrifugal separation. For 
a typical donor, approximately 24 L of whole 
blood can be processed over two days to collect 
approximately 500 million CD34+ cells, a cell 
progenitor population enriched for hematopoietic 
stem cells.
In Autologous HSCT, harvesting is done before 
conditioning. In allogeneic HSCT, donor has to be 
hospitalized for few days for pre-harvest health 
check, harvesting and health check after collection.
Transplantation of Stem Cells 
The collected stem cells are then transfused to patient 
through intravenous route. This is just like routine 
blood transfusion.
Engraftment and Hematopoietic Recovery
Engraftment is the hematopoietic reconstitution i.e. 
the start of blood cell formation by infused stem 
cells in the recipient’s bone marrow. Normally the 
day on which absolute neutrophil count reaches at 
least 500/uL for three consecutive days for the first 
time is taken as the date of engraftment. It usually 
takes several weeks before the number of blood cells 
starts to return to normal. In some people, it may take 
longer.
Transfusion of blood products is required 
throughout the process from conditioning to time of 
hematopoietic recovery.
After the Transplant 
Usually the patient is discharged from the hospital 
approximately one - two months after transplantation. 
He/she remains on immunosuppressive and anti 
microbial drugs for a certain period to avoid GVHD 
and infections. The speed of recovery and return to 
productive life varies, depending on patient’s age, 
condition, disease involved and post-transplant 
complications. 
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